Loading...
•
Dec 31, 2021
Amedisys Q4 2021 Earnings Report
Amedisys reported mixed results with revenue increase and net income decrease for Q4 2021.
Key Takeaways
Amedisys reported a slight increase in net service revenue for Q4 2021, rising to $559.3 million from $550.7 million in the same period of 2020. However, net income attributable to Amedisys, Inc. decreased to $34.0 million compared to $45.2 million in the previous year. The company issued 2022 guidance, anticipating adjusted net service revenue to be in the range of $2.330 billion to $2.365 billion and adjusted EBITDA in the range of $275 million to $285 million.
Net service revenue increased to $559.3 million from $550.7 million year-over-year.
Net income attributable to Amedisys, Inc. decreased to $34.0 million from $45.2 million year-over-year.
Adjusted net income attributable to Amedisys, Inc. was $38.8 million, compared to $49.5 million in 2020.
The company issued 2022 guidance with adjusted net service revenue anticipated between $2.330 billion and $2.365 billion.
Amedisys
Amedisys
Forward Guidance
Amedisys anticipates adjusted net service revenue to be in the range of $2.330 billion to $2.365 billion and adjusted EBITDA in the range of $275 million to $285 million.
Positive Outlook
- Adjusted net service revenue is anticipated to be in the range of $2.330 billion to $2.365 billion.
- Adjusted EBITDA is anticipated to be in the range of $275 million to $285 million.
- Adjusted diluted earnings per share is anticipated to be in the range of $5.23 to $5.45 based on an estimated 33.2 million shares outstanding.
- Company continues to lead the industry in quality.
- Company is working through new and innovative workforce optimization initiatives.
Challenges Ahead
- Guidance excludes the effects of any future acquisitions and potential share repurchases, if any are made.
- COVID-19 has continued to impact the operating metrics typically used to forecast both growth and cost assumptions for both core Amedisys and Contessa.
- Any future regulations or government interventions could impact the company's ability to achieve this guidance.
- Spike in clinicians and business development staff on quarantine could impact the company's ability to achieve this guidance.
- Staffing shortages due to current and proposed federal, state and local vaccine mandates could impact the company's ability to achieve this guidance.